Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer—experience from a prematurely closed phase II study-Reference-Cited by-同舟云学术

Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer—experience from a prematurely closed phase II study

Published:2004-07 Issue:1 Volume:45 Page:131-132
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Raez Luis E,Rosado Manuel F,Santos Edgardo S,Reis Isildinha M

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference4 articles.

1. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non–small-cell lung cancer;Masuda;J. Clin. Oncol.,2000

2. Docetaxel and Irinotecan, combination, in the treatment of non-small cell lung cancer;Adjei;Oncology,1999

3. Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule;Murren;Oncology (Huntngt),2001

4. Randomized phase II study of docetaxel plus cisplatin versus docetaxel plus irinotecan in advanced non-small cell lung cancer (NSCLC): a west Japan thoracic oncology group (WJTOG) study;Satouchi;Proc. Am. Soc. Clin. Oncol.,2001

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment;Journal of Biomedical Materials Research Part A;2022-04-29

2. Substrate Stiffness Modulates the Growth, Phenotype, and Chemoresistance of Ovarian Cancer Cells;Frontiers in Cell and Developmental Biology;2021-08-24

3. Selective binding and controlled release of anticancer drugs by polyanionic cyclodextrins;Bioorganic & Medicinal Chemistry;2018-05

4. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis;BMC Cancer;2015-12

5. Characterisation and antiproliferative activity of irinotecan and sulphonatocalixarene inclusion complex;Supramolecular Chemistry;2011-05-03